Targeting lymphomas through MALT1 inhibition

Oncotarget. 2012 Dec;3(12):1493-4. doi: 10.18632/oncotarget.819.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / enzymology
  • B-Lymphocytes / immunology
  • Caspase Inhibitors / therapeutic use*
  • Caspases / genetics
  • Caspases / metabolism
  • Drug Design
  • Humans
  • Lymphocyte Activation / drug effects*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / enzymology
  • Lymphoma, Large B-Cell, Diffuse / genetics
  • Lymphoma, Large B-Cell, Diffuse / immunology
  • Molecular Targeted Therapy
  • Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / metabolism
  • Signal Transduction / drug effects

Substances

  • Antineoplastic Agents
  • Caspase Inhibitors
  • Neoplasm Proteins
  • Caspases
  • MALT1 protein, human
  • Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein